Adempas

Adempas Indications/Uses

riociguat

Manufacturer:

Bayer

Distributor:

Zuellig
/
Four Star
Full Prescribing Info
Indications/Uses
Chronic thromboembolic pulmonary hypertension (CTEPH): Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with inoperable CTEPH; persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity (see Pharmacology: Pharmacodynamics under Actions).
Pulmonary arterial hypertension (PAH): Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease (see Pharmacology: Pharmacodynamics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in